Evidence-based recommendations on the treatment of von Willebrand disease in Italy

Blood Transfusion

Volumn 7, Issue 2, 2009, Pages 117-126

  Mannucci, Pier O ^a,d   Franchini, Massimo ^b   Castaman, Giancarlo ^c   Federici, Augusto B ^a  

^a MAGGIORE HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c SAN BORTOLO HOSPITAL   (Italy)

^d NONE   (Italy)

Author keywords

Desmopressin; Von Willebrand disease; Von Willebrand factor

Indexed keywords

ALLOANTIBODY; AMINOCAPROIC ACID; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; EMOSINT; ESTROGEN; FANDHI; GESTAGEN; THROMBOCYTE CONCENTRATE; TRANEXAMIC ACID; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; WILFACTIN;

ADJUVANT THERAPY; ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIABETES INSIPIDUS; EVIDENCE BASED MEDICINE; FLUSHING; HEADACHE; HEMOSTASIS; HUMAN; HYPERVOLEMIA; HYPONATREMIA; ITALY; PREGNANCY COMPLICATION; SIDE EFFECT; TACHYCARDIA; TACHYPHYLAXIS; VON WILLEBRAND DISEASE;

EID: 66349136610     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2008.0052-08     Document Type: Article

References (42)

1. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987;69:454-459 (Pubitemid 17022013)
2. Castaman G, Federici AB, Rodeghiero F, Mannucci PM. von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica 2003; 88: 94-108.
3. Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor. J Thromb Haemost 2006; 4:2103-2114 (Pubitemid 44403432)
4. Mannucci PM. How I treat patients with von Willebrand disease. Blood 2001;97:1915-1919 (Pubitemid 32239066)
5. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004;351:683-694 (Pubitemid 39063271)
6. McCormick KA, Fleming B. Clinical practice guidelines. The Agency for Health Care Policy and Research fosters the development of evidence-based guidelines. Health Prog 1992;73:30-34
7. Federici AB, Castaman G, Mannucci PM; Italian Association of Hemophilia Centers (AICE). Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 2002; 8: 607-621
8. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997;90:2515-2521
9. Cash JD, Garder AMA, Da Costa J. The release of plasminogen activator and factor VIII by LVP, AVP, DDAVP, ATIII and OT in man. Br J Haematol 1974; 27: 363-364
10. Federici AB, Mazurier C, Berntorp E, et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 2004;103:2032-2038 (Pubitemid 38326217)
11. Castaman G, Lethagen S, Federici AB, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood 2008;111:3531-3539
12. Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 1992;82:87-93.
13. Smith TJ, Gill JC, Ambruso DR, Hathaway WE. Hyponatremia and seizures in young children given DDAVP. Am J Hematol 1989;31:199-202.
14. Bond L, Bevan D. Myocardial infarction in a patient with hemophilia treated with DDAVP. N Engl J Med 1988;318:121. (Pubitemid 18029309)
15. Byrnes JJ, Larcada A, Moake JL. Thrombosis following desmopressin for uremic bleeding. Am J Hematol 1988;28:63-65 (Pubitemid 18153444)
16. Mannucci PM. Use of desmopressin (DDAVP) during early pregnancy in factor VIII-deficient women. Blood 2005;105:3382. (Pubitemid 40504365)
17. Mannucci PM, Chediak J, Hanna W, and the Alphanate Study Group. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 2002;99: 450-456
18. Bello IF, Yuste VJ, Molina MQ, Navarro FH. Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results. Haemophilia 2007;13 (Suppl 5:25-32. (Pubitemid 350253401)
19. Gill JC, Ewenstein BM, Thompson AR, et al.; Humate-P Study Group. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/von Willebrand factor concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia 2003; 9: 688-695
20. Thompson AR, Gill JC, Ewenstein BM, et al.; Humate- P Study Group. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/von Willebrand factor concentrate (Humate-P). Haemophilia 2004; 10: 42-51.
21. Lethagen S, Kyrle PA, Castaman G, Haertel S, et al.; the Haemate P Surgical Study Group. von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost 2007; 5: 1420-1430 (Pubitemid 46965370)
22. Lillicrap D, Poon M-C, Walker I, et al. Association of Hemophilia Clinic Directors of Canada. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/Humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002;87:224-230
23. Federici AB, Castaman G, Franchini M, et al. Clinical use of Haemate P in inherited von Willebrand disease: a cohort study on 100 Italian patients. Haematologica 2007;92:944-951 (Pubitemid 350144241)
24. Rivard GE, Aledort L, Alphanate Surgical Investigators. Efficacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease. Haemophilia 2008;14:271-275
25. Federici AB, Baudo F, Caracciolo C, et al. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study. Haemophilia 2002; 8:761-767 (Pubitemid 35446628)
26. Makris M, Colvin B, Gupta V, et al. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease. Thromb Haemost 2002;88:387-388
27. Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002; 88:378-379
28. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000;343:457-462 (Pubitemid 30646484)
29. Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis 2005;16:S23-6. (Pubitemid 40756405)
30. Federici AB. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease. The PRO.WILL study. Haemophilia 2007;13:15-24. (Pubitemid 350253400)
31. Goudemand J, Scharrer I, Berntorp E, et al. Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. J Thromb Haemost 2005;3:2219-2227 (Pubitemid 41727200)
32. Borel-Derlon A, Federici AB, Roussel-Robert V, et al. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost 2007;5:1115-1124 (Pubitemid 46902109)
33. Mannucci PM, Tamaro G, Narchi G, et al. Lifethreatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor. Eur J Hematol 1987;39:467-470 (Pubitemid 18002930)
34. Ciavarella N, Schiavoni M, Valenzano E, et al. Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor. Haemostasis 1996;26:10-14 (Pubitemid 26076633)
35. Franchini M, Gandini G, Giuffrida A, De Gironcoli M, Federici AB. Treatment for patients with type 3 von Willebrand disease and alloantibodies: a case report. Haemophilia 2008;14:645-646
36. Castillo R, Monteagudo J, Escolar G, et al. Hemostatic effect of normal platelet transfusion in severe von Willebrand disease patients. Blood 1991;77:1901-1905
37. Castillo R, Escolar G, Monteagudo J, et al. Hemostasis in patients with severe von Willebrand disease improves after normal platelet transfusion and normalizes with further correction of the plasma defect. Transfusion 1997;37:785-790 (Pubitemid 27369128)
38. Mannucci PM. Hemostatic drugs. N Engl J Med 1998;339:245-253 (Pubitemid 28350168)
39. Kouides PA, Heit JA, Phillipp CS, et al. A multisite, prospective, cross-over study of intranasal desmopressin and oral tranexamic acid in women with menorrhagia and abnormal laboratory hemostasis. Blood 2007;110:218a (abstract).
40. Foster PA. The reproductive health of women with von Willebrand disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995;74:784-790
41. Giles AR, Hoogendoorn H, Benford K. Type IIB von Willebrand's disease presenting as thrombocytopenia during pregnancy. Br J Haematol 1987;67:349-353 (Pubitemid 18022353)
42. Pareti FI, Federici AB, Cattaneo M, Mannucci PM. Spontaneous platelet aggregation during pregnancy in a patient with von Willebrand disease type II B can be blocked by monoclonal antibodies to both platelet glycoproteins Ib and IIb/IIIa. Br J Haematol 1990; 75:86-91. (Pubitemid 20157985)